Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the
maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)